BA-Merrill Lynch 23/03/2010 1 Buy, Medium Risk $36.60 2.0%
The broker notes June quarter IVIG reimbursement rates in the US appear stable, so there is no change to its estimate of flat pricing for the company.
There are no changes to the broker's earnings forecasts on the news and the broker retains its Buy rating and $36.60 price target.
Credit Suisse 23/03/2010 1 Outperform $40.50 12.9%
The broker notes plasma pricing data has been relatively steady in recent months, though inventory days have moved slightly higher through the first part of 2010.
The stock is trading in line with its 12-month average earnings multiple at present but the broker points out it is at a 22% discount to its five-year average. This implies value at current levels and so the broker retains its Outperform rating.
BA-Merrill Lynch 23/03/2010 1 Buy, Medium Risk $36.60 2.0%The...
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$311.33 |
Change
3.280(1.06%) |
Mkt cap ! $150.4B | |||
| Open | High | Low | Value | Volume |
| $310.00 | $312.47 | $310.00 | $172.6M | 554.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 130 | $311.32 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $311.50 | 210 | 2 |
View Market Depth
| Last trade - 16.10pm 29/07/2024 (20 minute delay) ? |
| CSL (ASX) Chart |